Ovarian Cancer

A supplemental new drug application (sNDA) for Rubraca (rucaparib), a PARP inhibitor, has been granted a priority review by the Food and Drug Administration.

Longer time in between pre- and postoperative chemotherapy may be associated with significantly worse survival outcomes in women with ovarian cancer.

As PARP inhibitors continue to improve outcomes in patients with ovarian cancer, they may one day be moved into the frontline treatment setting, said Susana M. Campos, M.D., a gynecologic oncologist at Dana-Farber Cancer Institute and an assistant professor at Harvard Medical School.

When facing ovarian cancer, it is critical to stay healthy and well-informed, says Anya Khomenko.

Checkpoint inhibitors in combination with PARP inhibitors are garnering interest, with the impact of PARP inhibitors already well established in this tumor type.

For some, being home for the holidays means lots of extra family time. Bright Pink, a national nonprofit focused on the prevention and early detection of breast and ovarian cancer, shares how women can take advantage of this opportunity to enrich their knowledge about their family's health history.

A newly studied blood test could be the answer to a serious question: How can a woman tell if she has ovarian cancer in its earliest stage?

People with cancer have to gear up for the emotional and mental workout of dealing with insurance. Here are some tips for coping.

Many patients who completed the survey felt maintenance therapy would help them buy time.

An antibody–drug conjugate is being tested in patients with platinum-resistant ovarian cancer.

If approved, the new indication would make frontline Avastin available in combination with carboplatin and paclitaxel, followed by Avastin alone, for women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. The FDA is expected to render a decision on the sBLA by June 25, 2018.

Did a miracle occur after Mary Jane passed away from ovarian cancer?

The largest ruling yet was overturned by a California judge on Oct. 20.

Studies have shown that African American women tend to have worse outcomes after ovarian cancer surgery than their white counterparts.

The pharmaceutical company Clovis Oncology filed a supplemental new drug application (sNDA) to the FDA for their drug Rubraca (rucaparib) to be used as maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Rebecca Arend, M.D., gynecologic oncologist at University of Alabama at Birmingham Hospital, discusses the rapidly changing field of ovarian cancer.

To better understand ovarian cancer, as well as predict when women might relapse, it is crucial that researchers start investigating more of the molecular phases of the disease, says Peter Dottino, M.D.

For patients with metastatic cancer, NED times are often overshadowed by their lurking disease waiting to pounce and return. Here are some thoughts on living life passionately, both during treatment and while NED

PARP inhibitors are changing the way ovarian cancer is treated.

More research is needed on the other genetic mutations, besides BRCA, that patients with ovarian cancer harbor so that they can be used to help plan treatments.

Some moments in life get seared into your brain. Years later you can picture exactly what you were wearing. You can conjure up the smell of the room.

Mail-order kits are now making genetic testing more accessible to patients who may need it the most.

The future for immunotherapy treatment for gynecologic cancers may be found in drug combinations, according to Dmitriy Zamarin, M.D., Ph.D., who admits that these agents have been slower to demonstrate progress in this group of patients.

Renee Cowan, gynecologic oncology fellow at Memorial Sloan Kettering Cancer Center (MSK), discusses the importance of patients with ovarian cancer seeing an oncologist who specializes in the field.

Women with ovarian or breast cancer often don’t receive the genetic testing they need in order to devise the best treatment plans, a new study says.